June 2015—New 5-year data on OsseoSpeed implants (ASTRA TECH Implant System) show
stable soft tissue and maintained bone levels from implant placement and implant loading,
confirming an average bone level reduction of only 0.3 mm.
Recent data from 17 scientific articles show that the average bone level
reduction from implant placement to five years is 0.3 mm, whereas the
accepted standard norm is currently at 1.5 mm.
In addition, data from 62 scientific articles confirm the 0.3 mm average
bone level reduction one year after implant loading, with remained stability
for five years.
“These great results are not a surprise to us, but we are of course very
happy to be able to present data based on sound science, proving our
marginal bone maintenance. We have followed the performance of the
ASTRA TECH Implant System, with the OsseoSpeed implants, for many
years, and we continue to find evidence of maintained marginal bone well
above the standard norm,” says AnnaKarin Lundgren, Director Global
Clinical Affairs at DENTSPLY Implants.
For dental professionals and their implant patients, it is important that implant treatment not only
restores function, but also results in natural-looking esthetics. To fulfill this promise, a prerequisite
is biological sustainability, i.e. the harmony of marginal bone and surrounding soft tissue over
time. AnnaKarin Lundgren continues; “Achieving biological sustainability is important for optimal
dental implant treatment outcome, professional success and satisfied patients. That’s why we
continue to focus on just that, in order to continue to challenge the scientific boundaries and
deliver quality of life for patients.”
A key factor in delivering biological sustainability is the ASTRA TECH Implant System
BioManagement Complex. This unique combination of interdependent features ensures reliable,
predictable and esthetic results both in the short and long term.
Strong commitment to science and clinical research
Parallel to the introduction in markets all over the world, DENTSPLY Implants has continued its
dedication to science and clinical research. DENTSPLY Implants’ products and solutions are well documented with reliable clinical results, and are supported by more than 1,650 scientific
publications. Currently, there are 200 ongoing studies worldwide, involving more than 450
clinicians. Documentation is an integrated and essential part of the product development process.
To read more about the science behind DENTSPLY Implants’ products and solutions, please visit
www.dentsplyimplants.com/science
About DENTSPLY Implants
DENTSPLY Implants offers comprehensive solutions for all phases of implant therapy, including
ANKYLOS®, ASTRA TECH Implant System™ and XiVE® implant lines, digital technologies, such as
ATLANTIS™ patient-specific CAD/CAM solutions and SIMPLANT® guided surgery, SYMBIOS®
regenerative solutions, and professional and business development programs, such as STEPPS™.
DENTSPLY Implants creates value for dental professionals and allows for predictable and lasting
implant treatment outcomes, resulting in enhanced quality of life for patients.
About DENTSPLY International
DENTSPLY International Inc. is a leading manufacturer and distributor of dental and other healthcare
products. For over 115 years, DENTSPLY’s commitment to innovation and professional collaboration has enhanced its portfolio of branded consumables and small equipment. Headquartered in the United States, the Company has global operations with sales in more than 120 countries.
For further information, please contact:
Janie Shen—Director, Corporate Communications, DENTSPLY Implants, North America
800-531-3481 | www.dentsplyimplants.com
As a member of the press, you can also visit our News & Press Room at:
www.dentsplyimplants.com/en/Resources/News-and-Press
Stay Relevant With Implant Practice US
Join our email list for CE courses and webinars, articles and mores
